Ruptured arteriovenous malformation complicating thrombolytic therapy with tissue plasminogen activator
J. Proner, B. R. Rosenblum and A. Rothman
Department of Internal Medicine, New Rochelle Hospital Medical Center, NY.
It is though that the clot-specific activity of tissue plasminogen
activator, used in the treatment of acute myocardial infarction, makes
bleeding complications less common than does the use of either
streptokinase or urokinase. The incidence of intracerebral hemorrhage
complicating the use of tissue plasminogen activator has been estimated to
be 0.68%. This is a report of the rupture of an intracranial arteriovenous
malformation complicating the use of tissue plasminogen activator therapy.
Theories for the mechanism of hemorrhage in this instance are presented, as
are suggestions for future use of the enzyme.
